Allovir Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
KLRS$1.87-18.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Years Ended December 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2023 | 2022 |
| Operating expenses: | ||
| Research and development | $133,070 | $118,870 |
| General and administrative | 48,261 | 52,332 |
| Impairment costs | 18,570 | — |
| Total operating expenses | 199,901 | 171,202 |
| Loss from operations | (199,901) | (171,202) |
| Total other income (loss), net: | ||
| Interest income | 5,734 | 1,876 |
| Other income (loss), net | 3,623 | 351 |
| Loss before income taxes | (190,544) | (168,975) |
| Income tax benefit | (126) | (265) |
| Net loss | $(190,418) | $(168,710) |
| Net loss per share — basic and diluted | $(1.83) | $(2.20) |
| Weighted-average common shares outstanding — basic and diluted | 104,057,220 | 76,654,856 |
| Comprehensive loss: | ||
| Net loss | $(190,418) | $(168,710) |
| Other comprehensive income (loss), net of tax: | ||
| Unrealized gain (loss) on available-for-sale securities | 406 | (313) |
| Total other comprehensive income (loss) | 406 | (313) |
| Comprehensive loss | $(190,012) | $(169,023) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.